GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer
Cell Reports · 2025-06 · 44 (6) · 115774
DOI: 10.1016/j.celrep.2025.115774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025-06. Verfasst von Yubin Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou…. Hauptthemen laut MEDLINE: Ferroptosis, Proto-Oncogene Proteins p21(ras), Mutation, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
KRAS mutations drive tumorigenesis, but their role in ferroptosis regulation remains unclear. Here, we construct wild-type KRAS (KRASWT) and KRASG12D-mutant cancer cells and demonstrate that G12D-mutant cells exhibit increased viability and reduced ferroptosis upon RSL3 or erastin treatment. These cells show diminished lipid peroxidation and mitochondrial damage, indicating ferroptosis resistance. KRASG12D activates MEK/ERK signaling to phosphorylate LDHA, enhancing glycolysis and lactate production. Exogenous lactate supplementation similarly protects WT cells from ferroptosis. Mechanistically, G12D-mutation-derived lactate induces glutamate-cysteine ligase (GCL) modifier (GCLM) lactylation, a process catalyzed by acetyl-coenzyme A (CoA) acetyltransferase 2 (ACAT2). Inhibition of GCLM lactylation either through the mutation of the lactylation site or by knockdown of ACAT2 diminished the enzymatic activity of GCL and suppressed glutathione synthesis. Importantly, ACAT2 depletion overcomes ferroptosis resistance in KRASG12D-mutant tumors in vivo. Our findings reveal a KRASG12D-driven metabolic adaptation linking GCLM lactylation to ferroptosis resistance, proposing ACAT2 inhibition as a therapeutic strategy for KRAS-mutant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; School of Medicine, South China University of Technolo…
- Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
- Junior Clinical Cooperation Unit Translational Gastrointestinal Oncology and Preclinical Models, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University,…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Yan, Q., Ruan, S., Cui, J., Li, Z., Zhang, Z., Yang, J., Fang, J., Liu, S., Huang, S., Hou, B., & Zhang, C. (2025). GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer. Cell Reports, 44(6), 115774. https://doi.org/10.1016/j.celrep.2025.115774
Vancouver
Chen Y, Yan Q, Ruan S, Cui J, Li Z, Zhang Z, et al. GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer. Cell Reports. 2025;44(6):115774. doi:10.1016/j.celrep.2025.115774
BibTeX
@article{Chen2025,
author = {Chen, Yubin and Yan, Qian and Ruan, Shiye and Cui, Jinwei and Li, Zhenchong and Zhang, Zhongyan and Yang, Jiayu and Fang, Jike and Liu, SiYang and Huang, Shanzhou and Hou, Baohua and Zhang, Chuanzhao},
title = {GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer},
journal = {Cell Reports},
year = {2025},
volume = {44},
number = {6},
pages = {115774},
doi = {10.1016/j.celrep.2025.115774}
}
EUVIMED